Galapagos has developed a target discovery platform that provides novel starting points for drug and antibody therapies, thereby addressing the industry’s need for innovative, disease-modifying medicines. Galapagos is exploiting this platform in disease areas for which there is a clear need for better medicines. The Company’s product portfolio consists mainly of new mode-of action-drugs in bone and joint diseases as well as programs in bone metastasis and cachexia. To enable the progression of a broad portfolio of programs, Galapagos has established risk sharing alliances with big pharma companies in specific disease areas. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases.

Galapagos’ service division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharma, biotech and patient foundations - encompassing target and drug discovery through to the delivery of pre-clinical candidates.

June 30 , 2009
Galapagos awarded Innovative Enterprise qualification in France
Read more

June 16, 2009
Galapagos initiates clinical studies with GLPG0187, a candidate drug for bone metastasis
Read more

June 3 , 2009
Galapagos announces appointment of new CFO and Board Member;
creates new warrant plan
Read more